Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D

This article was originally published in The Gray Sheet

Executive Summary

Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.

You may also be interested in...



Caliper Technologies Corp

Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering

Caliper Technologies Corp

Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering

Sequenom IPO Prospectus Shows Diagnostics Potential In Product Pipeline

Potential applicability of Sequenom, Inc.' s industrial genomics technology to the field of diagnostics is outlined in a preliminary prospectus for an initial public offering of up to $70 mil. in common stock, recently filed with the Securities and Exchange Commission.

Related Content

UsernamePublicRestriction

Register

MT012663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel